Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Anatomy and Physiology›Podocytes
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Podocytes

Anatomy and Physiology · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

Highly differentiated epithelial cells of the visceral layer of bowman capsule of the kidney.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (730 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Highly differentiated epithelial cells of the visceral layer of bowman capsule of the kidney. They are composed of a cell body with major cell surface extensions and secondary fingerlike extensions called pedicels. They enwrap the kidney glomerulus capillaries with their cell surface extensions forming a filtration structure. The pedicels of neighboring podocytes interdigitate with each other leaving between them filtration slits that are bridged by an extracellular structure impermeable to large macromolecules called the slit diaphragm, and provide the last barrier to protein loss in the kidney.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Podocyte; Epithelial Cells, Glomerular Visceral; Glomerular Visceral Epithelial Cells; Visceral Epithelial Cells, Glomerular.

Where it fits in the MeSH classification

Broader topics
Glomerular Filtration Barrier; Kidney Glomerulus; Epithelial Cells

Related concepts

  • Bowman Capsule
  • Kidney
  • Cell Surface Extensions
  • Kidney Glomerulus

Research landscape

PubMed indexes 6,484 records tagged with the MeSH heading “Podocytes” (counts retrieved 2026-10-31). 2,421 of them (37.3%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 3,304 records.

Reviews account for 896 records (13.8%) and meta-analyses for 4. Randomized controlled trials number 12 (0.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 829 records; 2010-2019: 3,304 records; 2020 onward: 2,421 records0through 19998292000-20093,3042010-20192,4212020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-2009829
2010-20193,304
2020 onward2,421
Share of records by publication typeReviews: 13.8 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.2 percentReviews13.8% (896)Meta-analyses0.1% (4)Randomized controlled trials0.2% (12)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 6,484 PubMed records
TypeRecordsShare
Reviews89613.8%
Meta-analyses40.1%
Randomized controlled trials120.2%

Method: PubMed query "Podocytes"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in anatomy and physiology

Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review
Hu S, Hang X, Wei Y, Wang H, Zhang L, Zhao L
2024Review article
Design not recorded in structured metadata
112cc by
PMID 38374141 · DOI · PMC10875896
Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy
Jiang H, Shen Z, Zhuang J, Lu C, Qu Y, Xu C, et al.
2023Review article
Design not recorded in structured metadata
42cc by
PMID 38288116 · DOI · PMC10822972
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava SP, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, et al.
2024Research article
Design not recorded in structured metadata
37cc by
PMID 39630889 · DOI · PMC11616692
SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3
Li L, Jiang S, Jin Q, Qu P, Guo Y, Lan X, et al.
2026Research article
Design not recorded in structured metadata
3cc by
PMID 41316884 · DOI · PMC12904062

Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review [1]

Review article Hu S, Hang X, Wei Y, Wang H, Zhang L, Zhao L · · 2024 · cited 112 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Diabetic kidney disease (DKD) is a long-term and serious complication of diabetes that affects millions of people worldwide.
Closing excerpt
In conclusion, this review provides a comprehensive and updated overview of the glomerular crosstalk in DKD and highlights its importance for the development of novel intervention approaches.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (200 words)

Diabetic kidney disease (DKD) is a long-term and serious complication of diabetes that affects millions of people worldwide. It is characterized by proteinuria, glomerular damage, and renal fibrosis, leading to end-stage renal disease, and the pathogenesis is complex and involves multiple cellular and molecular mechanisms. Among three kinds of intraglomerular cells including podocytes, glomerular endothelial cells (GECs) and mesangial cells (MCs), the alterations in one cell type can produce changes in the others. The cell-to-cell crosstalk plays a crucial role in maintaining the glomerular filtration barrier (GFB) and homeostasis. In this review, we summarized the recent advances in understanding the pathological changes and interactions of these three types of cells in DKD and then focused on the signaling pathways and factors that mediate the crosstalk, such as angiopoietins, vascular endothelial growth factors, transforming growth factor-β, Krüppel-like factors, retinoic acid receptor response protein 1 and exosomes, etc. Furthermore, we also simply introduce the application of the latest technologies in studying cell interactions within glomerular cells and new promising mediators for cell crosstalk in DKD. In conclusion, this review provides a comprehensive and updated overview of the glomerular crosstalk in DKD and highlights its importance for the development of novel intervention approaches.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38374141 · DOI · PMC10875896

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy [2]

Review article Jiang H, Shen Z, Zhuang J, Lu C, Qu Y, Xu C, et al. · · 2023 · cited 42 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The glomerular filtration barrier, comprising the inner layer of capillary fenestrated endothelial cells, outermost podocytes, and the glomerular basement membrane between them, plays a pivotal role in kidney function.
Closing excerpt
It offers valuable insights for a deeper understanding of the role of podocytes in proteinuric glomerular diseases, and the identification of new therapeutic targets, and has significant implications for the future clinical diagnosis and treatment of podocyte-related disorders.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (223 words)

The glomerular filtration barrier, comprising the inner layer of capillary fenestrated endothelial cells, outermost podocytes, and the glomerular basement membrane between them, plays a pivotal role in kidney function. Podocytes, terminally differentiated epithelial cells, are challenging to regenerate once injured. They are essential for maintaining the integrity of the glomerular filtration barrier. Damage to podocytes, resulting from intrinsic or extrinsic factors, leads to proteinuria in the early stages and eventually progresses to chronic kidney disease (CKD). Immune-mediated podocyte injury is a primary pathogenic mechanism in proteinuric glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and lupus nephritis with podocyte involvement. An extensive body of evidence indicates that podocytes not only contribute significantly to the maintenance of the glomerular filtration barrier and serve as targets of immune responses but also exhibit immune cell-like characteristics, participating in both innate and adaptive immunity. They play a pivotal role in mediating glomerular injury and represent potential therapeutic targets for CKD. This review aims to systematically elucidate the mechanisms of podocyte immune injury in various podocyte lesions and provide an overview of recent advances in podocyte immunotherapy. It offers valuable insights for a deeper understanding of the role of podocytes in proteinuric glomerular diseases, and the identification of new therapeutic targets, and has significant implications for the future clinical diagnosis and treatment of podocyte-related disorders.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38288116 · DOI · PMC10822972

Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease [3]

Research article Srivastava SP, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, et al. · · 2024 · cited 37 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Angiopoietin-like 4 (ANGPTL4), a key protein involved in lipoprotein metabolism, has diverse effects.
Closing excerpt
Together, these data demonstrate that podocyte- and tubule-derived Angptl4 is fibrogenic in diabetic kidneys.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (158 words)

Angiopoietin-like 4 (ANGPTL4), a key protein involved in lipoprotein metabolism, has diverse effects. There is an association between Angptl4 and diabetic kidney disease; however, this association has not been well investigated. We show that both podocyte- and tubule-specific ANGPTL4 are crucial fibrogenic molecules in diabetes. Diabetes accelerates the fibrogenic phenotype in control mice but not in ANGPTL4 mutant mice. The protective effect observed in ANGPTL4 mutant mice is correlated with a reduction in stimulator of interferon genes pathway activation, expression of pro-inflammatory cytokines, reduced epithelial-to-mesenchymal transition and endothelial-to-mesenchymal transition, lessened mitochondrial damage, and increased fatty acid oxidation. Mechanistically, we demonstrate that podocyte- or tubule-secreted Angptl4 interacts with Integrin β1 and influences the association between dipeptidyl-4 with Integrin β1. We demonstrate the utility of a targeted pharmacologic therapy that specifically inhibits Angptl4 gene expression in the kidneys and protects diabetic kidneys from proteinuria and fibrosis. Together, these data demonstrate that podocyte- and tubule-derived Angptl4 is fibrogenic in diabetic kidneys.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39630889 · DOI · PMC11616692

SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3 [4]

Research article Li L, Jiang S, Jin Q, Qu P, Guo Y, Lan X, et al. · · 2026 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Podocyte dysfunction represents both an early pathological hallmark and a key driver of proteinuria in diabetic kidney disease (DKD); nevertheless, the potential epigenetic regulatory mechanisms remain poorly defined.
Closing excerpt
Collectively, these findings establish SETDB2 as a critical regulator of podocyte integrity and a promising therapeutic target for DKD.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (149 words)

Podocyte dysfunction represents both an early pathological hallmark and a key driver of proteinuria in diabetic kidney disease (DKD); nevertheless, the potential epigenetic regulatory mechanisms remain poorly defined. Here, the histone methyltransferase SETDB2 is identified as a pivotal epigenetic suppressor of podocyte dysfunction and DKD progression. Glomerular SETDB2 expression exhibits a significant reduce in both DKD patients and mouse models, showing an inverse correlation with disease severity. Podocyte-specific SETDB2 deficiency exacerbates podocytes dysfunction and accelerates DKD progression, whereas its overexpression exerts renal protective effects. Mechanistically, SETDB2 directly enhances H3K9 trimethylation at the Smad3 promoter, thereby repressing SMAD3 expression and activation, ultimately preserving podocyte function. Notably, it identifies TCF21, a transcription factor downregulated in DKD, as a direct upstream regulator of Setdb2 expression via binding to promoter and activating its transcription. Collectively, these findings establish SETDB2 as a critical regulator of podocyte integrity and a promising therapeutic target for DKD.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41316884 · DOI · PMC12904062

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Podocytopathies [5]
    Kopp JB, Anders HJ, Susztak K, Podestà MA, Remuzzi G, Hildebrandt F, et al. · Nat Rev Dis Primers · 2020 · cited 498 times (Europe PMC)
  • Research article Podocyte injury and its consequences [6]
    Nagata M · Kidney Int · 2016 · cited 492 times (Europe PMC)
  • Research article Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton [7]
    Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P · Trends Cell Biol · 2007 · cited 435 times (Europe PMC)
  • Research article Molecular pathways that drive diabetic kidney disease [8]
    Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K · J Clin Invest · 2023 · cited 300 times (Europe PMC)
  • Research article Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach [9]
    De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC · J Am Soc Nephrol · 2018 · cited 252 times (Europe PMC)
  • Research article The podocyte slit diaphragm--from a thin grey line to a complex signalling hub [10]
    Grahammer F, Schell C, Huber TB · Nat Rev Nephrol · 2013 · cited 216 times (Europe PMC)

References

  1. Hu S, Hang X, Wei Y, Wang H, Zhang L, Zhao L. Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review. . 2024. PMID 38374141 · DOI · PMC10875896
  2. Jiang H, Shen Z, Zhuang J, Lu C, Qu Y, Xu C, et al.. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy. . 2023. PMID 38288116 · DOI · PMC10822972
  3. Srivastava SP, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, et al.. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. . 2024. PMID 39630889 · DOI · PMC11616692
  4. Li L, Jiang S, Jin Q, Qu P, Guo Y, Lan X, et al.. SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3. . 2026. PMID 41316884 · DOI · PMC12904062
  5. Kopp JB, Anders HJ, Susztak K, Podestà MA, Remuzzi G, Hildebrandt F, et al.. Podocytopathies. Nat Rev Dis Primers. 2020. PMID 32792490 · DOI · PMC8162925
  6. Nagata M. Podocyte injury and its consequences. Kidney Int. 2016. PMID 27165817 · DOI
  7. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 2007. PMID 17804239 · DOI
  8. Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023. PMID 36787250 · DOI · PMC9927939
  9. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018. PMID 29321142 · DOI · PMC5827609
  10. Grahammer F, Schell C, Huber TB. The podocyte slit diaphragm--from a thin grey line to a complex signalling hub. Nat Rev Nephrol. 2013. PMID 23999399 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Glomerular Basement MembraneAnatomy and Physiology
  • Mesangial CellsAnatomy and Physiology
  • Kidney CortexAnatomy and Physiology
  • KidneyAnatomy and Physiology
  • Chromaffin CellsAnatomy and Physiology
  • Epithelioid CellsAnatomy and Physiology

All 542 articles in Anatomy and Physiology →

At a glance

6,484
PubMed records on this heading
37%
published since 2020
896
review articles
12
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Glomerular Basement MembraneAnatomy and Physiology
  • Mesangial CellsAnatomy and Physiology
  • Kidney CortexAnatomy and Physiology
  • KidneyAnatomy and Physiology
  • Chromaffin CellsAnatomy and Physiology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support